NantKwest, Inc. Banner Image

NantKwest, Inc. has reached its limit for free report views

Work for NantKwest, Inc.? Upgrade Your Profile and unlock all your annual reports.

NantKwest, Inc.

  • Ticker NK
    Exchange NASDAQ More
  • Industry Biotechnology More
  • Sector Healthcare More
NantKwest, Inc. Logo Image
  • 51-200 Employees
  • Based in Culver City, California
NantKwest (NASDAQ: NK) is an innovative, clinical-stage immunotherapy company focused on harnessing the power of the innate immune system to treat cancer and infectious diseases. NantKwest is the leading producer of clinical dose forms of off-the-shelf natural killer (NK) cell therapies. The activated NK cell platform is designed to destroy cancer and virally-infected cells. The safetyMore of these optimized, activated NK cells—as well as their activity against a broad range of cancers—has been tested in phase I clinical trials in Canada and Europe, as well as in multiple phase I and II clinical trials in the United States. By leveraging an integrated and extensive genomics and transcriptomics discovery and development engine, together with a pipeline of multiple, clinical-stage, immuno-oncology programs, NantKwest’s goal is to transform medicine by bringing novel NK cell-based therapies to routine clinical care. NantKwest is a member of the NantWorks ecosystem of companies.
NantKwest, Inc.

Most Recent Annual Report

NantKwest, Inc. MOST RECENT 2019 Annual Report and Form 10K

Report Locked. NantKwest, Inc. has reached its limit for free report views.

Older/Archived Annual Reports